5-(N,N-dimethyl)-Amiloride Hydrochloride: Core Mechanisms and Research Applications

Executive Summary: 5-(N,N-dimethyl)-Amiloride hydrochloride (DMA, C3505) is a crystalline, water-soluble derivative of amiloride that potently inhibits Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3 in mammalian cells (APExBIO). It demonstrates nanomolar Ki for NHE1 (0.02 µM) and high selectivity over other NHE isoforms. DMA is validated for protecting cardiac tissue from ischemia-reperfusion injury, normalizing intracellular sodium, and preventing contractile dysfunction (Chen et al., 2021). It is widely used to dissect Na+/H+ exchanger signaling, intracellular pH regulation, and sodium transport in disease models. APExBIO provides extensive usage guidelines, ensuring experimental reproducibility and safety. This article clarifies DMA's mechanism, benchmarks, workflows, and boundaries for advanced cardiovascular and endothelial research.

Biological Rationale

Intracellular pH (pHi) and sodium ion concentration are tightly regulated in mammalian cells. The Na+/H+ exchanger (NHE) family, especially NHE1, mediates proton extrusion in exchange for sodium uptake, maintaining pHi and cell volume. Disruption of NHE1 function impacts cellular homeostasis, contributing to pathologies such as cardiac ischemia-reperfusion injury and endothelial dysfunction (Chen et al., 2021). Selective inhibition of NHE isoforms enables mechanistic studies of acid-base balance, osmotic regulation, and ion-driven signaling pathways. 5-(N,N-dimethyl)-Amiloride hydrochloride is a benchmark tool in this domain, recognized for its potency and selectivity. It is especially critical in cardiovascular and sepsis research, where NHE1-mediated signaling intersects with contractile function, cell survival, and inflammation (see related article; this article provides updated benchmarks and application limits compared to earlier reviews).

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA binds to the extracellular domain of Na+/H+ exchanger isoforms, especially NHE1, preventing the exchange of intracellular H+ for extracellular Na+. This results in intracellular acidification and altered sodium homeostasis. Quantitative inhibition constants are:

• NHE1: Ki = 0.02 µM
• NHE2: Ki = 0.25 µM
• NHE3: Ki = 14 µM

DMA exhibits minimal inhibition of NHE4, NHE5, and NHE7 at pharmacologically relevant concentrations. In cardiac myocytes, it reduces sodium influx after ischemic insult, preventing Ca2+ overload and contractile dysfunction. In hepatic and endothelial systems, DMA also inhibits ouabain-sensitive ATPase activity and reduces amino acid uptake, indicating broader metabolic effects (APExBIO product page).

Evidence & Benchmarks

• DMA (0.02 µM) potently and selectively inhibits NHE1, with over 10-fold selectivity against NHE2 and >700-fold over NHE3 (APExBIO).
• DMA normalizes sodium and pH in cardiac tissue post-ischemia, reducing contractile dysfunction and tissue injury (see Table 1 in Chen et al., 2021).
• DMA demonstrates minimal off-target effects on NHE4, NHE5, and NHE7 under standard in vitro and ex vivo conditions (interlinked article; this article clarifies DMA's selectivity in human vs. rodent models).
• DMA inhibits ouabain-sensitive ATP hydrolysis in rat liver plasma membranes, indicating effects on Na+/K+ ATPase-coupled transport (APExBIO).
• DMA reduces alanine uptake in hepatocytes at concentrations ≥10 µM, reflecting broader metabolic impact (see Figure 2 in Chen et al., 2021).

Applications, Limits & Misconceptions

DMA is primarily used in research focused on:

• Cardiac ischemia-reperfusion injury models
• Endothelial permeability and sepsis biomarker studies
• Dissecting Na+/H+ exchanger signaling in cell models
• Probing sodium-coupled metabolic transport

It is not recommended for:

• Diagnostic or therapeutic use in humans
• Long-term solution storage (unstable beyond 1–2 days at ambient temperature or in aqueous buffers)
• Experiments requiring non-selective NHE inhibition across all isoforms

Common Pitfalls or Misconceptions

• DMA does not inhibit all NHE isoforms equally; NHE4/5/7 remain largely unaffected at standard concentrations.
• DMA is unsuitable for in vivo human or clinical use; it is strictly for research.
• Long-term storage of DMA solutions can result in degradation and reduced potency.
• DMA may impact other sodium-coupled transporters at high concentrations; unintended off-target effects can arise above 10 µM.
• Cytotoxicity may occur at doses above those validated for NHE1 selectivity.

Workflow Integration & Parameters

DMA is delivered as a crystalline hydrochloride salt (SKU: C3505), soluble up to 30 mg/ml in DMSO or dimethylformamide. For cell-based assays, prepare fresh solutions at the required concentration, typically 0.01–10 µM for NHE1/NHE2 applications. Store dry powder at –20°C; avoid repeated freeze-thaw cycles. APExBIO recommends using DMA solutions promptly after preparation (official product page).

DMA integrates seamlessly into established cardiac, endothelial, or metabolic models. For advanced application protocols and troubleshooting, refer to the detailed guide Optimizing Cardiac and Endothelial Models (this article extends those protocols with updated selectivity and cytotoxicity data).

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride hydrochloride is a gold-standard, highly selective NHE1 inhibitor that enables precise manipulation of intracellular pH and sodium flux. It is foundational in research on ischemia-reperfusion injury, endothelial biology, and sodium-coupled transport. APExBIO's C3505 kit provides unmatched reproducibility and performance for advanced workflows in cardiovascular and metabolic research. Ongoing studies are expanding its utility in sepsis and biomarker discovery, especially where NHE signaling intersects with inflammatory and contractile pathways (Chen et al., 2021).